Dr. Peter Attia

This was the first phase one. So you're going very low dose. We're going to dose- Very low. That's the first time it's going into a human.

This was the first phase one. So you're going very low dose. We're going to dose- Very low. That's the first time it's going into a human.

And this is also mid-90s. Yeah, yeah. This is all happening when you arrive.

And this is also mid-90s. Yeah, yeah. This is all happening when you arrive.

I mean, what a time to be a Genentech.

I mean, what a time to be a Genentech.

Wow.

Wow.

How are you picking the cancer to study something like this? Herceptin's obvious because you're targeting a receptor.

How are you picking the cancer to study something like this? Herceptin's obvious because you're targeting a receptor.

Yeah, they're easy. You know what you're doing. But here you could be targeting anything.

Yeah, they're easy. You know what you're doing. But here you could be targeting anything.

Why is that? You've got the IL-2 stuff going on where you've got 10% of people will respond to it, but 90% won't.

Why is that? You've got the IL-2 stuff going on where you've got 10% of people will respond to it, but 90% won't.

These were patients with metastatic breast cancer?

These were patients with metastatic breast cancer?

And the standard you're going to hold yourself to in the phase two is 50% shrinkage?

And the standard you're going to hold yourself to in the phase two is 50% shrinkage?

This is a great time to actually hit pause. I wanted to do this later, but I think this is the right drug to go through two things. One, even though I've done this probably half a dozen times on the podcast, you should never assume somebody remembers it. I want people to understand what the difference is between a phase one, a phase two, a phase three study. Also understand what's preclinical.

This is a great time to actually hit pause. I wanted to do this later, but I think this is the right drug to go through two things. One, even though I've done this probably half a dozen times on the podcast, you should never assume somebody remembers it. I want people to understand what the difference is between a phase one, a phase two, a phase three study. Also understand what's preclinical.